Literature DB >> 1321725

Effects of solubilization and vanadate/glutathione complex on inhibitor potencies against eosinophil cyclic AMP-specific phosphodiesterase.

J E Souness1, C Maslen, L C Scott.   

Abstract

Treatment of membranes from guinea-pig peritoneal eosinophils with deoxycholate and NaCl solubilized greater than 95% of the particulate cyclic AMP-specific phosphodiesterase (PDE IV). Solubilized PDE IV was at least 10 times more potently inhibited by selective PDE IV inhibitors (e.g. rolipram, denbufylline) than bound enzyme. Vanadate/glutathione complex (V/GSH) activated membrane-bound PDE IV and also increased potencies of these same inhibitors by at least 10-fold. Neither solubilization nor V/GSH markedly influenced the inhibitory activities of non-selective inhibitors (e.g. trequinsin, dipyridamole). Inhibitor effects on solubilized PDE IV and cyclic AMP accumulation in intact cells were strongly correlated. These results suggest a biologically important site on eosinophil PDE IV which is concealed or partially concealed in freshly prepared membranes and is exposed by solubilization or V/GSH.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321725     DOI: 10.1016/0014-5793(92)80435-j

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Evidence for selective effects of vanadium on adipose cell metabolism involving actions on cAMP-dependent protein kinase.

Authors:  R W Brownsey; G W Dong
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

Review 2.  In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus.

Authors:  A B Goldfine; D C Simonson; F Folli; M E Patti; C R Kahn
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

3.  Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.

Authors:  J E Souness; M Griffin; C Maslen; K Ebsworth; L C Scott; K Pollock; M N Palfreyman; J A Karlsson
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

4.  Natural vanadium-containing Mt. Fuji ground water improves hypo-activity of liver insulin receptor in Goto-Kakisaki rats.

Authors:  Katsuhiko Kato; Shizuo Yamada; Yuki Ohmori; Tomomi Oki; Eiichi Kawamoto; Kazuhiko Shirama; Yasuo Watanabe
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

5.  Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.

Authors:  J J Kelly; P J Barnes; M A Giembycz
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

6.  Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.

Authors:  J E Souness; M E Villamil; L C Scott; A Tomkinson; M A Giembycz; D Raeburn
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

7.  Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.

Authors:  J E Souness; C Maslen; S Webber; M Foster; D Raeburn; M N Palfreyman; M J Ashton; J A Karlsson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

8.  Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.

Authors:  J E Souness; L C Scott
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

9.  Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.

Authors:  A Hatzelmann; H Tenor; C Schudt
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

10.  cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.

Authors:  R Hoffmann; I R Wilkinson; J F McCallum; P Engels; M D Houslay
Journal:  Biochem J       Date:  1998-07-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.